Brevan Howard Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brevan Howard Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.53M	Buy	4,621 +184	+4%	+$62.6K	0.01%	685
2025 Q4	$1.76M	Sell	4,437 -1,733	-28%	-$767K	0.02%	523
2025 Q3	$2.81M	Buy	+6,170	New	+$2.51M	0.01%	426
2025 Q1	–	Sell	-1,333	Closed	-$314K	–	1137
2024 Q4	$314K	Buy	1,333 +44	+3%	+$11.6K	﹤0.01%	758
2024 Q3	$355K	Buy	+1,289	New	+$336K	﹤0.01%	790

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's ALNY Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 4.1% in Q1 2026, buying an estimated $62.6K and bringing the position to 4,621 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #685.

Brevan Howard Capital Management first reported a position in ALNY in Q3 2024 and has held it in 5 quarters since. The position peaked at $2.81M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Brevan Howard Capital Management held 4,621 shares of Alnylam Pharmaceuticals worth $1.53M as of Q1 2026.
Brevan Howard Capital Management bought 184 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $62.6K.
Alnylam Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #685 holding.
Brevan Howard Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
Brevan Howard Capital Management's Alnylam Pharmaceuticals position peaked at $2.81M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.